Clinic
Baptist Health Regional Hospitals
Baptist Health Regional Hospitals was paid $2.46M by Medicaid between Nov 2018 and Dec 2024, across 130 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 20% of everything it billed.
33Billing provider infoBAPTIST HEALTH REGIONAL HOSPITALS
VAN BUREN, AR 72956
VAN BUREN, AR 72956
33aNPI1154807584assigned 07/18/2018
33bProvider typeRehabilitation Clinic/Center
28Total paid$2.46M
24GClaims126,877
24DCodes billed130
24AFirst – last monthNov 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Arkansas
Rank by total paid#18 of 27
Median peer was paid$3.03M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELLS, TROY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,521 | $67K | |
| 2019 | 27,886 | $375K | |
| 2020 | 16,024 | $214K | |
| 2021 | 19,776 | $348K | |
| 2022 | 23,172 | $500K | |
| 2023 | 21,478 | $575K | |
| 2024incomplete | 15,020 | $378K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 20% | 4,408 | 4,143 | $490K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 1,922 | 1,733 | $303K |
| 70450 | Computed tomography, head or brain; without contrast material | 8.9% | 2,048 | 1,810 | $220K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.1% | 3,793 | 1,014 | $149K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.3% | 2,778 | 2,598 | $131K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.8% | 1,279 | 1,149 | $94K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.6% | 5,651 | 4,884 | $89K |
| 80053 | Comprehensive metabolic panel | 3.1% | 4,508 | 3,736 | $75K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 9,071 | 7,535 | $69K |
| 71045 | Radiologic examination, chest; single view | 2.4% | 5,656 | 5,034 | $60K |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 6,803 | 5,872 | $49K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 1,035 | 894 | $46K |
118 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 4,037 | $44K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 469 | $41K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 350 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 4,153 | $30K |
| 81025 | 1.2% | 3,376 | $29K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 1,279 | $28K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 1,339 | $25K |
| 86710 | <1% | 1,125 | $24K | |
| 73630 | <1% | 719 | $23K | |
| 81001 | <1% | 5,338 | $22K | |
| 12001 | <1% | 97 | $21K | |
| 84484 | <1% | 2,717 | $21K | |
| 83690 | <1% | 2,810 | $21K | |
| 73130 | <1% | 623 | $15K | |
| 73610 | <1% | 774 | $14K | |
| 80076 | <1% | 1,146 | $14K | |
| 99283 | Emergency room visit (moderate) | <1% | 728 | $14K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 53 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 260 | $11K |
| 80305 | <1% | 801 | $11K | |
| 87088 | <1% | 1,006 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 829 | $10K |
| 73110 | <1% | 418 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,606 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 86 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,783 | $8K |
| 81003 | <1% | 2,665 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,728 | $7K |
| 87430 | <1% | 751 | $7K | |
| 85027 | <1% | 1,162 | $7K | |
| 31720 | <1% | 28 | $6K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,026 | $6K |
| 82150 | <1% | 989 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,855 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,011 | $6K |
| 82550 | <1% | 982 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 650 | $6K |
| 85610 | <1% | 869 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 127 | $5K |
| 87081 | <1% | 601 | $4K | |
| 83880 | <1% | 188 | $4K | |
| 73030 | <1% | 240 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,560 | $4K |
| 84703 | <1% | 545 | $4K | |
| 87040 | <1% | 357 | $4K | |
| 82962 | <1% | 484 | $4K | |
| 80050 | General health panel | <1% | 89 | $3K |
| 73562 | <1% | 134 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 496 | $3K |
| 85730 | <1% | 632 | $3K | |
| 12011 | <1% | 13 | $3K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $2K |
| 87807 | <1% | 193 | $2K | |
| 87486 | <1% | 53 | $2K | |
| 87581 | <1% | 53 | $2K | |
| 83605 | <1% | 318 | $2K | |
| 70486 | <1% | 12 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,437 | $2K |
| 72100 | <1% | 77 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 138 | $2K |
| 80306 | <1% | 138 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 18 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 171 | $2K |
| 82077 | <1% | 99 | $2K | |
| 0225U | <1% | 411 | $2K | |
| 97162 | <1% | 12 | $2K | |
| 99284 | Emergency room visit (serious) | <1% | 378 | $1K |
| 80320 | <1% | 143 | $1K | |
| 87186 | <1% | 244 | $1K | |
| 87077 | <1% | 141 | $1K | |
| 96376 | <1% | 153 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 85 | $1K |
| 97161 | <1% | 17 | $1K | |
| 82553 | <1% | 144 | $955.84 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 31 | $926.49 |
| 94664 | <1% | 965 | $898.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12 | $672.61 |
| 73560 | <1% | 15 | $617.54 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 849 | $493.91 |
| 86677 | <1% | 35 | $435.12 | |
| 82803 | <1% | 18 | $423.60 | |
| 87420 | <1% | 34 | $411.84 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,370 | $383.88 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 559 | $347.78 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 825 | $340.07 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 121 | $335.00 |
| 90714 | <1% | 49 | $327.37 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 488 | $285.94 |
| 90715 | <1% | 15 | $272.21 | |
| 74018 | <1% | 13 | $263.38 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 86 | $249.66 |
| 85379 | <1% | 27 | $238.06 | |
| 73140 | <1% | 16 | $224.00 | |
| 88312 | <1% | 88 | $175.06 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 922 | $145.68 |
| 80329 | <1% | 17 | $136.26 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 823 | $119.82 |
| 85007 | <1% | 41 | $114.49 | |
| 81015 | <1% | 105 | $68.61 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 349 | $63.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 122 | $59.98 |
| J2704 | Injection, propofol, 10 mg | <1% | 208 | $59.33 |
| 82248 | <1% | 12 | $57.36 | |
| 82947 | <1% | 20 | $39.20 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 62 | $26.02 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 13 | $16.88 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $13.92 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 197 | $4.31 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $3.95 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 55 | $3.66 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 13 | $2.07 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 71 | $0.12 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 873 | $0.00 |
| A9270 | Non-covered item or service | 0% | 538 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 147 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 34 | $0.00 |
| 36600 | 0% | 18 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 88 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, TROY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Baptist Health Regional Hospitals | Fort Smith, AR | $17.49M |
| Baptist Health | Little Rock, AR | $16.48M |
| Baptist Health | North Little Rock, AR | $14.02M |
| Baptist Health | Arkadelphia, AR | $4.82M |
| Conway Community Services | Conway, AR | $4.12M |
| Baptist Health | Heber Springs, AR | $3.69M |
| Baptist Health Hospitals | Stuttgart, AR | $2.97M |
| Baptist Health | Little Rock, AR | $2.93M |
| Baptist Health | Malvern, AR | $2.68M |
| Baptist Health | Little Rock, AR | $1.83M |
| Baptist Health | Arkadelphia, AR | $1.51M |
| Baptist Health Hospitals | Stuttgart, AR | $901K |
| Baptist Health | Little Rock, AR | $780K |
| Baptist Health | North Little Rock, AR | $411K |
| Baptist Health | Monticello, AR | $367K |
| Baptist Health | Conway, AR | $142K |
| Baptist Health | Little Rock, AR | $88K |
| Baptist Health | Prescott, AR | $33K |
| Baptist Health | Malvern, AR | $31K |
| Baptist Health | Heber Springs, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.